Dr. Adela D. Mattiazzi, MD
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Years since graduation
- 34
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 239
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
FL license ME105012 -
Internal Medicine Physician
FL license ME105012 · FL license 9280
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Jackson Health System Miami, FL
Medical groups
- University of Miami (2,377 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 239
- Services billed
- 872
- Patients’ average age
- 57
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 206 | 80 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 153 | 48 |
| Established patient office or other outpatient visit, 40-54 minutes | 130 | 107 |
| Mechanical separation of plasma from blood | 108 | 19 |
| Dialysis procedure including 1 evaluation | 73 | 17 |
| Hemodialysis procedure with physician evaluation | 68 | 25 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 41 | 36 |
| Telephone medical discussion with physician, 21-30 minutes | 38 | 36 |
| Established patient office or other outpatient visit, 30-39 minutes | 28 | 26 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Miami, FL | 214 |
| Famotidine Other prescribers in Miami, FL | 186 |
| Nifedipine Er (nifedipine) Other prescribers in Miami, FL | 183 |
| Carvedilol Other prescribers in Miami, FL | 178 |
| Cinacalcet Hcl Other prescribers in Miami, FL | 167 |
| Rosuvastatin Calcium Other prescribers in Miami, FL | 123 |
| Privigen (immun glob g(igg)/pro/iga 0-50) | 121 |
| Octagam (immun globg(igg)/malt/iga ov50) | 87 |
| Hydralazine Hcl Other prescribers in Miami, FL | 78 |
| Tacrolimus Other prescribers in Miami, FL | 76 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 4 payments worth $333 in total to this clinician.
| Novo Nordisk Inc | $230 |
|---|---|
| Kaneka Medical America LLC | $103 |
| Food and Beverage | $333 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $340 in research payments for these studies, mostly to the institutions running them.
- A Multicenter, Single-arm, Open Label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily LNP023 in Adult aHUS Patients Who Are Naive to Complement Inhibitor Therapy
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.